Citations

Clear

3030 citation(s) found for "Susan, M".

A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)
Schafer, Eric S. , Rau, Rachel E. , Liu, Xiaowei , D’Adamo, David R., Scott, Rachael , Reyderman, Larisa, Martinez, Gresel, Devarajan, Sandhya, Fox, Elizabeth , Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Schafer, Eric S , Berg, Stacey L. , Minard, Charles G.

Mayo Clinic

Pediatric Blood & Cancer | May 2, 2018 | Volume: 65 | Issue: 8 | Pages: No page available

10.1002/pbc.27066 | PMID 29719113 Get It

Abstract Background Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin aggregate formation. We performed a phase 1 trial to determine the dose‐limiting toxicities (DLTs), maximum tolerated or recommended phase 2 dose (MTD/RP2D), and pharmacokinetics (PK) of eribulin in children with refractory or recurrent solid (excluding central nervous system) tumors. Methods Eribulin was administered intravenously on days 1 and 8 in 21‐day cycles. Three dose levels (1.1, 1.4, and 1.8 mg/m 2 /dose) were evaluated using the rolling six design with additional patients enrolled into a PK expansion cohort at the MTD. PK samples were obtained following the day 1, cycle 1 dose. Results Twenty‐three patients, ages 3–17 (median 14) years were enrolled; 20 were evaluable for toxicity. DLTs occurred in 0/6 and 1/6 subjects at the 1.1 and 1.4 mg/m 2 /dose, respectively. One subject at the 1.4 mg/m 2 /dose had grade 4 neutropenia and grade 3 fatigue. At the 1.8 mg/m 2 /dose, 2/5 subjects experienced dose‐limiting (grade 4) neutropenia. Grade 3/4 non‐DLTs included lymphopenia and hypokalemia, while low‐grade toxicities included anorexia and nausea. No episodes of grade > 2 corrected QT interval prolongation or peripheral neuropathy were reported. Eribulin pharmacokinetic parameters were highly variable; the median elimination half‐life was 39.6 (range 24.2–96.4) hr. A partial response was observed in one patient (Ewing sarcoma). Conclusions Eribulin was well tolerated in children with refractory or recurrent solid tumors with neutropenia identified as the primary DLT. The RP2D of eribulin is 1.4 mg/m 2 /dose on days 1 and 8 of a 21‐day cycle.
The Prevalence of Postnatal Depression in Women with a History of Bariatric Surgery [33R]
Kok, Susan N., Kim, Sharon J. , Grothe, Karen, Moore, Katherine M. , Long, Margaret E. , Collazo–Clavell, Maria L.

Mayo Clinic

Obstetrics & Gynecology | April 27, 2018 | Volume: 131 | Issue: 1 | Pages: 203S-203S

10.1097/01.aog.0000533284.01163.74 Get It

INTRODUCTION: Obesity is associated with postnatal depression; however, the prevalence of postnatal depression in women after bariatric surgery has not been further evaluated. METHODS: For this observational investigation, women, ages 18-45 years, with pregnancy from 1989-2015 and bariatric surgery were identified using the Olmsted County Rochester Epidemiology Project and ICD-9 codes. Those with surgery after pregnancy and/or without permission to use their records were excluded. Charts were reviewed for maternal and infant characteristics and outcomes. Postnatal depression was identified from a positive screen, referral for mood disorder, antidepressant medication increase, suicidality, or provider diagnosis from delivery to 12 months postpartum. RESULTS: Ninety-one women with pregnancy >23 weeks after surgery and available data were reviewed. The average body mass index at time of surgery was 47±8.6 kg/m2 (N=88) and at time of pregnancy 32±6.6 kg/m2 (N=89). The average age at surgery was 29±4.1 years and at delivery 33±4.4 years. Roux-en-Y gastric bypass was the most common surgery (N=70, 77%). Pregnancy outcomes included: 14% preterm deliveries (<37 weeks, N=13), 67% vaginal deliveries (N=61), no stillbirths, and 97% singleton deliveries (N=88). Mean singleton birthweight was 3225 grams (±471, N=86). Postnatal depression was noted in 38% of women (N=35), which is significantly higher than that for obese women in general (13-18%) when a 1-sample proportion test is conducted for comparison (38%vs18%, p <0.0001). CONCLUSION: Postnatal depression may be increased in women with a history of bariatric surgery. Further investigation is needed, but particular care should be taken to screen and diagnose these high-risk women.
Attitudes Toward Return of Genetic Research Results to Relatives, Including After Death: Comparison of Cancer Probands, Blood Relatives, and Spouse/Partners
Breitkopf, Carmen Radecki , Chaffee, Kari G. , Robinson, Marguerite , Lindor, Noralane M. , Gordon, Deborah R., Koenig, Barbara A. , Petersen, Gloria M. , Rabe, Kari G. , Robinson, Marguerite E, Wolf, Susan M.

Mayo Clinic

Journal of Empirical Research on Human Research Ethics | April 27, 2018 | Volume: 13 | Issue: 3 | Pages: 295-304

10.1177/1556264618769165 | PMID 29701109 Get It

Genetic research generates results with implications for relatives. Recommendations addressing relatives’ access to a participant’s genetic research findings include eliciting participant preferences about access and choosing a representative to make decisions about access upon participant incapacity/death. Representatives are likely to be blood relatives or spouse/partners (who may share genetically related children). This raises the question of whether relatives hold similar attitudes about access or divergent attitudes that may yield conflict. We surveyed pancreatic cancer biobank participants (probands) and relatives in a family registry (blood relatives and spouse/partners of probands); 1,903 (>55%) surveys were returned. Results revealed few attitudinal differences between the groups. A slightly higher proportion of blood relatives agreed with statements reflecting proband privacy. In conclusion, probands’ decisions on access are likely to be accepted by relatives; in choosing a representative, probands may not face major differences in attitudes about privacy/sharing between a blood relative and a spouse/partner.
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group
Chuk, Meredith K. , Widemann, Brigitte C. , Liu, Xiaowei , Bernhardt, M. Brooke , Kudgus, Rachel A. , Voss, Stephan D. , Blaney, Susan M. , Fox, Elizabeth , Weigel, Brenda J. , Bernhardt, Melanie Brooke , Reid, Joel M. , Voss, Stephan D , Minard, Charles G. , Kim, AeRang

Mayo Clinic

Pediatric Blood & Cancer | April 25, 2018 | Volume: 65 | Issue: 8 | Pages: No page available

10.1002/pbc.27077 | PMID 29693796 Get It

Abstract Background We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors. Methods Patients received cabozantinib tablets on a continuous dosing schedule in a rolling‐six escalating phase 1 trial design. PK and PD studies were performed. Results Forty‐one patients, median (range) age 13 (4–18) years, received cabozantinib to achieve a weekly cumulative dose equivalent to 30 (n = 6), 40 (n = 23). or 55 (n = 12) mg/m 2 /day. At 40 mg/m 2 /d, dose‐limiting toxicities (DLTs) were palmar‐plantar erythrodysesthesia syndrome, mucositis, and elevated alanine aminotransferase, lipase, and bilirubin. At 55 mg/m 2 /d, hypertension, reversible posterior leukoencephalopathy syndrome, headache, fatigue, and proteinuria were DLTs. Frequent non‐DLTs included diarrhea, hypothyroidism, fatigue, nausea, vomiting, elevated hepatic transaminases, and proteinuria. In subsequent cycles, DLTs occurred at all dose levels. Across all dose levels, the steady‐state exposure and peak cabozantinib concentrations were similar. Four patients experienced a confirmed partial response: medullary thyroid cancer (MTC; n = 2), Wilms tumor, and clear cell sarcoma. Stable disease (>6 cycles) was seen in seven patients (MTC [n = 2], Ewing sarcoma, synovial sarcoma, alveolar soft part sarcoma, paraganglioma, and ependymoma). Conclusions A protocol‐defined MTD was not reached; DLTs and dose reductions for toxicity occurred in the first and subsequent cycles at all dose levels. Based on the toxicity profile, pharmacokinetics, and responses, the recommended dose of cabozantinib in pediatric patients with refractory solid tumors is 40 mg/m 2 /day. A phase 2 study of cabozantinib is being conducted.
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Maurer, Matthew J. , Ghesquières, Hervé , Link, Brian K. , Jais, Jean‐Philippe, Thompson, Carrie A. , Haïoun, Corinne , Allmer, Cristine, Johnston, Patrick B. , Delarue, Richard, Micallef, Ivana N. , Peyrade, Frédéric, Inwards, David J. , Ketterer, Nicolas , Farooq, Umar , Fitoussi, Olivier , Macon, William R. , Molina, Thierry Jo , Syrbu, Sergei , Weiner, George J. , Ansell, Stephen M. , Salles, Gilles , Tilly, Hervé , Nowakowski, Grzegorz S. , Molina, Thierry J, Salles, Gilles A, Maurer, Matthew , Link, Brian K , Farooq, Umar , Salles, Gilles A , Weiner, George , Jaïs, Jean‐Philippe , Habermann, Thomas M. , Feldman, Andrew L. , Slager, Susan L. , Cerhan, James R. , Witzig, Thomas E. , Syrbu, Sergei

Mayo Clinic

Journal of Clinical Oncology | April 19, 2018 | Volume: 36 | Issue: 16 | Pages: 1603-1610

10.1200/jco.2017.76.5198 | PMID 29672223 Get It

Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the consent process and the inability to delay therapy for eligibility evaluation. We have examined the diagnosis-to-treatment interval (DTI) and its association with clinical factors and outcome in a clinic-based observational cohort of patients with DLBCL from the United States. Validation of results was performed in an independent, clinical trial-based cohort from Europe. Patients and Methods Patients were prospectively enrolled in the University of Iowa and Mayo Clinic Specialized Programs of Research Excellence Molecular Epidemiology Resource (MER; N = 986) or the Lymphoma Study Association (LYSA) LNH-2003 clinical trials program (N = 1,444). All patients received anthracycline-based immunochemotherapy at initial diagnosis. Associations of DTI with clinical factors and outcome were examined. Outcome was assessed using event-free survival at 24 months from diagnosis (EFS24). Results Median (range) DTI was 15 days (0 to 155 days in the MER and 23 days (0 to 215 days) in LYSA. Shorter DTI was strongly associated with adverse clinical factors, including elevated lactate dehydrogenase levels, poor performance status, B symptoms, and higher International Prognostic Index in both cohorts (all P < .001). Longer DTI was associated with improved EFS24 in both the MER (per-week odds ratio, 0.80; 95% CI, 0.74 to .0.87) and LYSA (per-week odds ratio, 0.90; 95% CI, 0.86 to 0.94); association with EFS24 remained significant after adjustment for International Prognostic Index. Conclusion DTI is strongly associated with prognostic clinical factors and outcome in newly diagnosed DLBCL. DTI should be reported in all clinical trials of newly diagnosed DLBCL and future trials should take steps to avoid selection bias due to treatment delay.
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis
Kleinstern, Geffen , Camp, Nicola J. , Goldin, Lynn R. , Vachon, Celine M. , Vajdic, Claire M. , Sanjosé, Sílvia de, Weinberg, J. Brice , Benavente, Yolanda , Casabonne, Delphine, Liebow, Mark , Nieters, Alexandra, Hjalgrim, Henrik , Melbye, Mads , Glimelius, Bengt , Adami, Hans‐Olov , Brennan, Paul , McKay, James , Cocco, Pier Luigi, Call, Timothy G. , Hanson, Curtis A. , Robinson, Dennis P. , Chaffee, Kari G. , Brooks‐Wilson, Angela , Monnereau, Alain, Clavel, Jacqueline , Glenn, Martha, Curtin, Karen , Conde, Lucía , Bracci, Paige M. , Morton, Lindsay M. , Severson, Richard K., Chanock, Stephen J., Spinelli, John J., Johnston, James B. , Rothman, Nathaniel , Skibola, Christine F., Leis, José F., Smedby, Karin E. , Berndt, Sonja I. , Caporaso, Neil E., Rabe, Kari G. , Cocco, Pierluigi , Monnereau, Alain , Norman, Aaron D. , Hanson, Curtis, Robinson, Dennis, Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Morton, Lindsay M , Clavel, Jacqueline , Vachon, Celine M. , Casabonne, Delphine , Boffetta, Paolo , Maynadié, Marc , Shanafelt, Tait D. , Cozen, Wendy , Rothman, Nathaniel , Kay, Neil E. , Cerhan, James R. , Slager, Susan L.

Mayo Clinic

Blood | April 19, 2018 | Volume: 131 | Issue: 23 | Pages: 2541-2551

10.1182/blood-2017-11-814608 | PMID 29674426 Get It

Key Points PRS, based on the known CLL loci, predicts CLL risk with high discrimination. This PRS predicts risk of monoclonal B-cell lymphocytosis, a precursor to CLL and a condition that has clinical impact beyond risk for CLL.
Prognostic Utility of Stress Testing and Cardiac Biomarkers in Menopausal Women at Low to Intermediate Risk for Coronary ARTery Disease (SMART Study): 5-Year Outcome
Ball, Caroline , Hagen, Mary E., Eifert-Rain, Susan, Wilansky, Susan , Castelló, Ramón, Pellikka, Patricia A. , Best, Patricia J.M. , Abdelmoneim, Sahar S. , Ball, Caroline A, Mantovani, Francesca , Pellikka, Patricia A , Mulvagh, Sharon L.

Mayo Clinic

Journal of Women's Health | April 19, 2018 | Volume: 27 | Issue: 5 | Pages: 542-551

10.1089/jwh.2017.6506 | PMID 29672210 Get It

Background: In women with low to intermediate risk of coronary artery disease (CAD), prognostic detection strategies have been controversial. We present the follow-up data of the SMART trial in peri/postmenopausal women at low to intermediate risk of CAD. Objectives: To determine the value of contrast stress echocardiography (CSE), stress electrocardiogram (sECG), and serum biomarkers for prediction of cardiovascular events (CE) in peri/postmenopausal women at low to intermediate risk of CAD. Materials and Methods: From January 2004 to August 2007, 400 peri/postmenopausal women were prospectively enrolled. All women had detailed risk factor assessment, and underwent simultaneous CSE (Definity ® , Lantheus Medical Imaging) and sECG. Laboratories included brain natriuretic peptide (BNP), atrial natriuretic peptide, endothelin, and high sensitivity C-reactive protein. Wall motion score index was based on a 16-segment model. Abnormal CSE was defined as new or worsening wall motion abnormality at stress, while abnormal sECG was ≥1 mm horizontal/downsloping ST segment depression/elevation (80 mseconds duration). Self-reported outcome data were collected from a mailed Women's Heart Clinic Questionnaire. CE outcomes included all-cause mortality, nonfatal myocardial infarction (MI), heart failure, chest pain hospitalization or development of typical angina (CP), and revascularization (REVASC). Adjusted Cox proportional hazard ratios (HR; 95% confidence intervals) were reported. Results: A total of 366 women (54.4 ± 5.5 years, Framingham risk 6.5% ± 4.4%) completed simultaneous CSE and sECG. Forty-two (11.5%) had abnormal CSE, while sECG was abnormal in 22 (6%) women. Follow-up (4.4 ± 1.2 years) was available in 315/366 (86%) women (78% exercise-CSE, 22% dobutamine-CSE). In those who completed follow-up, CSE was abnormal in 33 women (10.5%) and sECG was abnormal in 21 (6.7%). In 33 women with abnormal CSE, sECG was abnormal in 7 (21.2%) and normal in 26 (79%), p = 0.0004. CE occurred in 27 (8.6%) women: 8 all-cause mortality, 2 nonfatal MI, 13 CP, and 4 REVASC. CE occurred in 21% versus 7% of women with abnormal versus normal CSE, p = 0.014 and 38% versus 6% of women with abnormal versus normal sECG, p < 0.0001. Rest BNP was higher in women with CE versus those without ( p = 0.018). Abnormal sECG and abnormal CSE were associated with CE, while only abnormal sECG was an independent predictor of CE (adjusted HR 10.3 [1.9–61.4], p = 0.007). Of the laboratory results, only BNP was associated with CE (adjusted HR 2.9 [1.1–7.3], p = 0.028). Conclusions: sECG and rest BNP were independent predictors of subsequent CE within 5 years in peri/postmenopausal women at low to intermediate risk of CAD.
CX3CR1 identifies PD-1 therapy–responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy
Yan, Yiyi , Cao, Siyu , Liu, Xin , Harrington, Susan M. , Bindeman, Wendy , Adjei, Alex A. , Jang, Jin Sung , Jen, Jin, Li, Ying , Chanana, Pritha , Mansfield, Aaron S. , Dronca, Roxana , Dong, Haidong , Mansfield, Aaron S , Dong, Haidong , Park, Sean S. , Markovic, Svetomir N.

Mayo Clinic

JCI Insight | April 18, 2018 | Volume: 3 | Issue: 8 | Pages: No page available

10.1172/jci.insight.97828 | PMID 29669928 Get It

Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti–PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for the successful chemoimmunotherapy is not completely understood. Here we show that a subset of circulating CD8 + T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade). These CX3CR1 + CD8 + T cells have effector memory phenotypes and the ability to efflux chemotherapy drugs via the ABCB1 transporter. In line with clinical observation, our preclinical models identified an optimal sequencing of chemoimmunotherapy that resulted in an increase of CX3CR1 + CD8 + T cells. Taken together, we found a subset of PD-1 therapy–responsive CD8 + T cells that were capable of withstanding chemotherapy and executing tumor rejection with their unique abilities of drug efflux (ABCB1), cytolytic activity (granzyme B and perforin), and migration to and retention (CX3CR1 and CD11a) at tumor sites. Future strategies to monitor and increase the frequency of CX3CR1 + CD8 + T cells may help to design effective chemoimmunotherapy to overcome cancer resistance to immune checkpoint blockade therapy.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
Bachy, Emmanuel , Habermann, Thomas M., Gelas‐Dore, Bénédicte, Estell, Jane, Neste, Éric Van Den, Bouabdallah, Réda, Gyan, Emmanuel , Bargay, Joan , Slager, Susan L., Silva, María Gomes da , Fitoussi, Olivier , Intragumtornchai, Tanin , Ansell, Stephen M., Lamy, T. , Dartigues, Peggy , Link, Brian K. , Seymour, John F., Salles, Gilles , Link, Brian K , Gyan, Emmanuel , Salles, Gilles A , Maurer, Matthew J. , Habermann, Thomas M. , Maucort‐Boulch, Delphine , Feldman, Andrew L. , Delmer, Alain , Slager, Susan L. , Belada, David , Maisonneuve, Hervé , Ansell, Stephen M. , Cerhan, James R. , Bachy, Emmanuel

Mayo Clinic

Blood | April 17, 2018 | Volume: 132 | Issue: 1 | Pages: 49-58

10.1182/blood-2017-11-816405 | PMID 29666118 Get It

Key Points In FL, no prognostic index has been built based solely on a large cohort of patients treated with initial immunochemotherapy. The PRIMA-PI is a simplified index based on β2m and bone marrow involvement for patients treated with immunochemotherapy.
Adiposity, Body Composition and Ventricular–Arterial Stiffness in the Elderly: The Atherosclerosis Risk in Communities Study
Fernandes-Silva, Miguel Morita , Shah, Amil M. , Claggett, Brian , Cheng, Susan , Tanaka, Hirofumi , Silvestre, Odílson Marcos , Nadruz, Wilson , Borlaug, Barry A. , Solomon, Scott D. , Borlaug, Barry A , Solomon, Scott David , Shah, Amil

Mayo Clinic

European Journal of Heart Failure | April 17, 2018 | Volume: 20 | Issue: 8 | Pages: 1191-1201

10.1002/ejhf.1188 | PMID 29663586 Get It

Abstract Aim Weight gain appears to accelerate age-related ventricular–arterial stiffening, which has been implicated in the development of heart failure (HF), but it is unclear whether body fat accumulation underpins this association. We evaluated the relationship of adiposity, using measures of body composition, with ventricular–arterial stiffness among the elderly in the community. Methods and results Adiposity was accessed through body mass index (BMI), waist circumference, and body fat percentage. We studied the association of these measures with carotid–femoral pulse wave velocity (cfPWV), arterial elastance index (EaI), left ventricular (LV) end-systolic elastance index (EesI) and LV end-diastolic elastance index (EedI) in 5520 community-based, elderly Atherosclerosis Risk in Communities (ARIC) Study participants, who underwent echocardiography between 2011 and 2013. BMI and waist circumference were directly associated with EaI, EedI and EesI even after adjusting for age, sex, race, hypertension, diabetes mellitus, heart rate, prevalent coronary heart disease and HF. After further adjustment for BMI, body fat percentage demonstrated significant independent linear relationships with EaI [standardized beta coefficient (β)=0.17, P&lt;0.001], EesI (β=0.08, P=0.003) and EedI (β=0.20, P&lt;0.001), and significant non-linear relationships with cfPWV (P=0.033). Conclusion In this biracial community-based cohort, increased adiposity was associated with increased ventricular–arterial stiffness among the elderly and suggests a potential mechanism by which obesity might contribute to the development of HF.